The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis.
Open accessAbstract
The antitumor effect and mechanisms activated by murine IL-12 and IL-18, cytokines that induce IFN-gamma production, were studied using engineered SCK murine mammary carcinoma cells. In syngeneic A/J mice, SCK cells expressing mIL-12 or mIL-18 were less tumorigenic and formed tumors more slowly than control cells. Neither SCK.12 nor SCK.18 cells protected significantly against tumorigenesis by distant SCK cells. However, inoculation of the two cell types together synergistically protected 70% of mice from concurrently injected distant SCK cells and 30% of mice from SCK cells established 3 d earlier. Antibody neutralization studies revealed that the antitumor effects of secreted mIL-12 and mIL-18 required IFN-gamma. Interestingly, half the survivors of SCK.12 and/or SCK.18 cells developed protective immunity suggesting that anti-SCK immunity is unlikely to be responsible for protection. Instead, angiogenesis inhibition, assayed by Matrigel implants, appeared to be a property of both SCK.12 and SCK.18 cells and the two cell types together produced significantly greater systemic inhibition of angiogenesis. This suggests that inhibition of tumor angiogenesis is an important part of the systemic antitumor effect produced by mIL-12 and mIL-18.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486
O'Reilly, M. (1994) · Cell · doi:10.1016/0092-8674(94)90200-3 · Cited by 3,345
Development of T H 1 CD4 + T Cells Through IL-12 Produced by Listeria -Induced Macrophages
Hsieh, C.-S., Macatonia, S. E., Tripp, C. S., Wolf, S. F., O'Garra, A., & Murphy, K. M. (1993) · Science · doi:10.1126/science.8097338 · Cited by 3,134
CELLULAR RESPONSES TO INTERFERON-γ
Boehm, U., Klamp, T., Groot, M., & Howard, J. C. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.749 · Cited by 2,890
Cloning of a new cytokine that induces IFN-γ production by T cells
Okamura, H., Tsutsui, H., Komatsu, T., Yutsudo, M., Hakura, A., Tanimoto, T., Torigoe, K., Okura, T., Nukada, Y., Hattori, K., et al. (1995) · Nature · doi:10.1038/378088a0 · Cited by 2,600
Trinchieri, G. (1995) · Annual Review of Immunology · doi:10.1146/annurev.iy.13.040195.001343 · Cited by 2,399
Self-citationKleinman, H. K., McGarvey, M. L., Liotta, L. A., Robey, P. G., Tryggvason, K., & Martin, G. R. (1982) · Biochemistry · doi:10.1021/bi00267a025 · Cited by 1,231
Xie, Q. W., Whisnant, R., & Nathan, C. (1993) · The Journal of experimental medicine · doi:10.1084/jem.177.6.1779 · Cited by 1,118
Passaniti, A., Taylor, R. M., Пили, Р., Guo, Y., Long, P., Haney, J. A., Pauly, R. R., Grant, D. S., & Martin, G. R. (1992) · PubMed · Cited by 806
Recombinant IL-12 administration induces tumor regression in association with IFN- gamma production.
Nastala, C. L., Edington, H. D., McKinney, T. G., Tahara, H., Nalesnik, M. A., Brunda, M. J., Gately, M. K., Wolf, S. F., Schreiber, R. D., Storkus, W. J., et al. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.153.4.1697 · Cited by 780
Inhibition of Angiogenesis In Vivo by Interleukin 12
Voest, E. E., Kenyon, B. M., O'Reilly, M. S., Truitt, G., D'Amato, R. J., & Folkman, J. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.8.581 · Cited by 722
Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo.
Angiolillo, A. L., Sgadari, C., Taub, D. D., Liao, F., Farber, J. M., Maheshwari, S., Kleinman, H. K., Reaman, G. H., & Tosato, G. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.1.155 · Cited by 705
Ushio, S., Namba, M., Okura, T., Hattori, K., Nukada, Y., Akita, K., Tanabe, F., Konishi, K., Micallef, M., Fujii, M., et al. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.11.4274 · Cited by 624
Micallef, M. J., Ohtsuki, T., Kohno, K., Tanabe, F., Ushio, S., Namba, M., Tanimoto, T., Torigoe, K., Fujii, M., Ikeda, M., et al. (1996) · European Journal of Immunology · doi:10.1002/eji.1830260736 · Cited by 597
Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10
Sgadari, C., Angiolillo, A., & Tosato, G. (1996) · Blood · doi:10.1182/blood.v87.9.3877.bloodjournal8793877 · Cited by 469
Wysocka, M., Kubin, M., Vieira, L. Q., Ozmen, L., Garotta, G., Scott, P., & Trinchieri, G. (1995) · European Journal of Immunology · doi:10.1002/eji.1830250307 · Cited by 467
Self-citationTsutsui, H., Nakanishi, K., Matsui, K., Higashino, K., Okamura, H., Miyazawa, Y., & Kaneda, K. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.9.3967 · Cited by 417
Angiogenesis and angiogenesis inhibition: An overview
Folkman, J. (1997) · Experientia Supplementum · doi:10.1007/978-3-0348-9006-9_1 · Cited by 410
Yoshimoto, T., Okamura, H., Tagawa, Y.-I., Iwakura, Y., & Nakanishi, K. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.8.3948 · Cited by 381
Abrams, J. S., Roncarolo, M., Yssel, H., Andersson, U., Gleich, G. J., & Silver, J. E. (1992) · Immunological Reviews · doi:10.1111/j.1600-065x.1992.tb01406.x · Cited by 362
Tahara, H., Zeh, H. J., Storkus, W. J., Pappo, I., Watkins, S. C., Gubler, U., Wolf, S. F., Robbins, P., & Lotze, M. T. (1994) · PubMed · Cited by 326
Revel, M., & Chebath, J. (1986) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(86)90134-9 · Cited by 272
Tahara, H., Zitvogel, L., Storkus, W. J., Zeh, H. J., McKinney, T. G., Schreiber, R. D., Gubler, U., Robbins, P. D., & Lotze, M. T. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.12.6466 · Cited by 271
Baskar, S., Ostrand-Rosenberg, S., Nabavi, N., Nadler, L. M., Freeman, G. J., & Glimcher, L. H. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.12.5687 · Cited by 263
Mig, the Monokine Induced By Interferon-γ, Promotes Tumor Necrosis In Vivo
Sgadari, C., Farber, J. M., Angiolillo, A. L., Liao, F., Teruya-Feldstein, J., Burd, P. R., Yao, L., Gupta, G., Kanegane, C., & Tosato, G. (1997) · Blood · doi:10.1182/blood.v89.8.2635 · Cited by 246
IL-12 induces T helper 1-directed antitumor response
Tsung, K., Meko, J. B., Peplinski, G. R., Tsung, Y. L., & Norton, J. A. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.7.3359 · Cited by 184
Amount of interleukin 12 available at the tumor site is critical for tumor regression.
Colombo, M. P., Vagliani, M., Spreafico, F., Parenza, M., Chiodoni, C., Melani, C. C., & Stoppacciaro, A. (1996) · PubMed · Cited by 174
Cavallo, F., Giovarelli, M., Forni, G., Signorelli, P., Musiani, P., Modesti, A., Brunda, M. J., & Colombo, M. P. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.14.1049 · Cited by 171
Micallef, M. J., Yoshida, K., Kawai, S., Hanaya, T., Kohno, K., Arai, S., Tanimoto, T., Torigoe, K., Fujii, M., Ikeda, M., et al. (1997) · Cancer Immunology Immunotherapy · doi:10.1007/s002620050345 · Cited by 153
Role of interferon-gamma in interleukin 12-induced pathology in mice.
Car, B. D., Eng, V. M., Schnyder, B., LeHir, M., Shakhov, A. N., Woerly, G., Huang, S., Aguet, M., Anderson, T. D., & Ryffel, B. (1995) · Europe PMC (PubMed Central) · Cited by 123
Martinotti, A., Stoppacciaro, A., Vagliani, M., et al. (1995) · European Journal of Immunology · doi:10.1002/eji.1830250124 · Cited by 122
B7-1 and interleukin 12 synergistically induce effective antitumor immunity.
Coughlin, C. M., Wysocka, M., Kurzawa, H., Lee, W. M. F., Trinchieri, G., & Eck, S. L. (1995) · PubMed · Cited by 115
Self-citationYu, W., Yamamoto, N., Takenaka, H., Mu, J., Tai, X., Zou, J.-P., Ogowa, M., Tsutsui, T., Wijesuriya, R., Yoshida, R., et al. (1996) · International Immunology · doi:10.1093/intimm/8.6.855 · Cited by 89
Bloom, E. T., & Horvath, J. A. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.152.9.4242 · Cited by 78
Coughlin, C. M., Wysocka, M., Trinchieri, G., & Lee, W. M. F. (1997) · PubMed · Cited by 69
Self-citationTan, J., Newton, C. A., Djeu, J. Y., et al. (1996) · PubMed · Cited by 68
Interleukin-12 Inhibits Angiogenesis Induced by Human Tumor Cell Lines In Vivo
Majewski, S. T., Marczak, M., Szmurło, A., Jabłońska, S., & Bollag, W. (1996) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12340161 · Cited by 68
Vascular damage and delayed cell death in tumours after hyperthermia
Song, C. W., Kang, M. S., Rhee, J. G., & Levitt, S. H. (1980) · British Journal of Cancer · doi:10.1038/bjc.1980.45 · Cited by 66
Watanabe, M., McCormick, K. L., Völker, K., Ortaldo, J. R., Wigginton, J. M., Brunda, M. J., Wiltrout, R. H., & Fogler, W. E. (1997) · Europe PMC (PubMed Central) · Cited by 58
Cited by
Inflammation and tumor progression: signaling pathways and targeted intervention
Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., & Li, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00658-5 · Cited by 2,792
The Biology of Chemokines and their Receptors
Rossi, D., & Zlotnik, A. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.217 · Cited by 2,410
Interleukin-18 Regulates Both Th1 and Th2 Responses
Nakanishi, K., Yoshimoto, T., Tsutsui, H., & Okamura, H. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.423 · Cited by 1,315
Nanomaterials for Theranostics: Recent Advances and Future Challenges
Lim, E.-K., Kim, T., Paik, S., Haam, S., Huh, Y.-M., & Lee, K. (2015) · Chemical Reviews · doi:10.1021/cr300213b · Cited by 1,233
Kamihata, H., Matsubara, H., Nishiue, T., Fujiyama, S., Tsutsumi, Y., Ozono, R., Masaki, H., Mori, Y., Iba, O., Tateishi, E., et al. (2001) · Circulation · doi:10.1161/hc3501.093817 · Cited by 965
Metadata
- Authors
- Coughlin, C. M., Salhany, K. E., Wysocka, M., Aruga, E., Kurzawa, H., Chang, A. E., Hunter, C. A., Fox, J. C., Trinchieri, G., & Lee, W. M.
- Venue
- Journal of Clinical Investigation
- Published
- 1998-03-15
- Volume
- 101
- Issue
- 6
- Pages
- 1441-1452
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2149579127
- Cited by
- 415
- References
- 40
- FWCI
- 10.58
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.